{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:11:14Z","timestamp":1788405074456,"version":"build-2803163510"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40120-023-00565-7","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T11:02:22Z","timestamp":1704970942000},"page":"283-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives"],"prefix":"10.1007","volume":"13","author":[{"given":"Mark S.","family":"Freedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia K.","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Weinstock-Guttman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silva","family":"Markovic-Plese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dangond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Korich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Reder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"issue":"9","key":"565_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","volume":"8","author":"S Klineova","year":"2018","unstructured":"Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"565_CR2","first-page":"321","volume":"4","author":"F Manfredonia","year":"2008","unstructured":"Manfredonia F, Pasquali L, Dardano A, Iudice A, Murri L, Monzani F. Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2008;4(2):321\u201336.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"565_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jir.2013.0158","volume":"34","author":"AT Reder","year":"2014","unstructured":"Reder AT, Feng X. How type\u00a0I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J Interferon Cytokine Res. 2014;34(8):589\u201399.","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"565_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78\u201388.","journal-title":"Lancet Neurol"},{"key":"565_CR5","unstructured":"Multiple Sclerosis Society of America. History of multiple sclerosis: mymsaa.org; [updated February 26, 2020]. https:\/\/mymsaa.org\/ms-information\/overview\/history\/. Accessed Nov 30, 2021."},{"issue":"4","key":"565_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0025-7125(16)31671-6","volume":"63","author":"CM Poser","year":"1979","unstructured":"Poser CM. Multiple sclerosis. Med Clin North Am. 1979;63(4):729\u201343.","journal-title":"Med Clin North Am"},{"issue":"1","key":"565_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3949\/ccjm.59.1.63","volume":"59","author":"DE Goodkin","year":"1992","unstructured":"Goodkin DE, Ransohoff RM, Rudick RA. Experimental therapies for multiple sclerosis: current status. Cleve Clin J Med. 1992;59(1):63\u201374.","journal-title":"Cleve Clin J Med"},{"issue":"12","key":"565_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/ni1204-1193","volume":"5","author":"Y Watanabe","year":"2004","unstructured":"Watanabe Y. Fifty years of interference. Nat Immunol. 2004;5(12):1193.","journal-title":"Nat Immunol"},{"issue":"927","key":"565_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258\u201367.","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"565_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-07758-1","volume-title":"Interferons. Viruses and man: a history of interactions","author":"MW Taylor","year":"2014","unstructured":"Taylor MW. Interferons. Viruses and man: a history of interactions. 1st ed. Cham: Springer; 2014.","edition":"1"},{"issue":"12","key":"565_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nrd2422","volume":"6","author":"EC Borden","year":"2007","unstructured":"Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6(12):975\u201390.","journal-title":"Nat Rev Drug Discov"},{"key":"565_CR12","first-page":"29","volume":"10","author":"CH Goldschmidt","year":"2020","unstructured":"Goldschmidt CH, Hua LH. Re-evaluating the use of IFN-beta and relapsing multiple sclerosis: safety, efficacy and place in therapy. Degener Neurol Neuromuscul Dis. 2020;10:29\u201338.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"8","key":"565_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/acn3.84","volume":"1","author":"LH Kasper","year":"2014","unstructured":"Kasper LH, Reder AT. Immunomodulatory activity of interferon-beta. Ann Clin Transl Neurol. 2014;1(8):622\u201331.","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"565_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.2174\/187152712801661220","volume":"11","author":"JO Virtanen","year":"2012","unstructured":"Virtanen JO, Jacobson S. Viruses and multiple sclerosis. CNS Neurol Disord Drug Targets. 2012;11(5):528\u201344.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"12","key":"565_CR15","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.4049\/jimmunol.1302580","volume":"192","author":"Y Tao","year":"2014","unstructured":"Tao Y, Zhang X, Chopra M, et al. The role of endogenous IFN-beta in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis. J Immunol. 2014;192(12):5610\u20137.","journal-title":"J Immunol"},{"issue":"4","key":"565_CR16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/ph3041162","volume":"3","author":"MG Tovey","year":"2010","unstructured":"Tovey MG, Lallemand C. Safety, tolerability, and immunogenicity of interferons. Pharmaceuticals (Basel). 2010;3(4):1162\u201386.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"19\u201320","key":"565_CR17","first-page":"1700","volume":"148","author":"Y Nagano","year":"1954","unstructured":"Nagano Y, Kojima Y. Pouvoir immunisant du virus vaccinal inactiv\u00e9 par des rayons ultraviolets [Immunizing property of vaccinia virus inactivated by ultraviolets rays]. C R Seances Soc Biol Fil. 1954;148(19\u201320):1700\u20132.","journal-title":"C R Seances Soc Biol Fil"},{"issue":"1","key":"565_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/106002809202600111","volume":"26","author":"JF Browder","year":"1992","unstructured":"Browder JF, Araujo OE, Myer NA, Flowers FP. The interferons and their use in condyloma acuminata. Ann Pharmacother. 1992;26(1):42\u20135.","journal-title":"Ann Pharmacother"},{"issue":"8538","key":"565_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0140-6736(87)92863-7","volume":"1","author":"HS Panitch","year":"1987","unstructured":"Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987;1(8538):893\u20135.","journal-title":"Lancet"},{"issue":"4524","key":"565_CR20","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1126\/science.6171035","volume":"214","author":"L Jacobs","year":"1981","unstructured":"Jacobs L, O\u2019Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science (New York, NY). 1981;214(4524):1026\u20138.","journal-title":"Science (New York, NY)"},{"issue":"10","key":"565_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/archneur.1982.00510220007002","volume":"39","author":"L Jacobs","year":"1982","unstructured":"Jacobs L, O\u2019Malley J, Freeman A, Murawski J, Ekes R. Intrathecal interferon in multiple sclerosis. Arch Neurol. 1982;39(10):609\u201315.","journal-title":"Arch Neurol"},{"issue":"9","key":"565_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/archneur.1985.04060080019009","volume":"42","author":"L Jacobs","year":"1985","unstructured":"Jacobs L, O\u2019Malley JA, Freeman A, Ekes R, Reese PA. Intrathecal interferon in the treatment of multiple sclerosis. Patient follow-up. Arch Neurol. 1985;42(9):841\u20137.","journal-title":"Arch Neurol"},{"issue":"12","key":"565_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/archneur.1994.00540240089022","volume":"51","author":"L Jacobs","year":"1994","unstructured":"Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol. 1994;51(12):1245\u201352.","journal-title":"Arch Neurol"},{"issue":"1","key":"565_CR24","first-page":"205521731770066","volume":"3","author":"VM Rivera","year":"2017","unstructured":"Rivera VM, Macias MA. Access and barriers to MS care in Latin America. Mult Scler J Exp Transl Clin. 2017;3(1):2055217317700668.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"565_CR25","doi-asserted-by":"publisher","first-page":"102935","DOI":"10.1016\/j.msard.2021.102935","volume":"51","author":"AT Reder","year":"2021","unstructured":"Reder AT, Arndt N, Roman C, et al. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;51:102935.","journal-title":"Mult Scler Relat Disord"},{"key":"565_CR26","unstructured":"Bayer HealthCare Pharmaceuticals. Betaseron [package insert]. Whippany, NJ: 2018."},{"key":"565_CR27","unstructured":"Biogen Inc. Avonex [package insert]. Cambridge, MA: 2016."},{"key":"565_CR28","unstructured":"EMD Serono, Inc. Rebif [package insert]. Rockland, MA: 2021."},{"key":"565_CR29","unstructured":"Merck Europe B.V. Rebif [summary of product characteristics]. Amsterdam, the Netherlands: 2021."},{"issue":"2","key":"565_CR30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/cells9020482","volume":"9","author":"M Kunkl","year":"2020","unstructured":"Kunkl M, Frascolla S, Amormino C, Volpe E, Tuosto L. T helper cells: the modulators of inflammation in multiple sclerosis. Cells. 2020;9(2):482.","journal-title":"Cells"},{"issue":"3","key":"565_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1756285612474333","volume":"6","author":"K Lehmann-Horn","year":"2013","unstructured":"Lehmann-Horn K, Kronsbein HC, Weber MS. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord. 2013;6(3):161\u201373.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"565_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","volume":"25","author":"BC Kieseier","year":"2011","unstructured":"Kieseier BC. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs. 2011;25(6):491\u2013502.","journal-title":"CNS Drugs"},{"issue":"11","key":"565_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a032003","volume":"8","author":"D Jakimovski","year":"2018","unstructured":"Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Interferon beta for multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(11):a032003.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"565_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3389\/fimmu.2019.01564","volume":"10","author":"PS Rommer","year":"2019","unstructured":"Rommer PS, Milo R, Han MH, et al. Immunological aspects of approved MS therapeutics. Front Immunol. 2019;10:1564.","journal-title":"Front Immunol"},{"key":"565_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ebiom.2019.09.059","volume":"49","author":"X Feng","year":"2019","unstructured":"Feng X, Bao R, Li L, Deisenhammer F, Arnason BGW, Reder AT. Interferon-beta corrects massive gene dysregulation in multiple sclerosis: short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019;49:269\u201383.","journal-title":"EBioMedicine"},{"issue":"6","key":"565_CR36","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.4049\/jimmunol.0802226","volume":"182","author":"X Zhang","year":"2009","unstructured":"Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol. 2009;182(6):3928\u201336.","journal-title":"J Immunol"},{"issue":"7","key":"565_CR37","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.4049\/jimmunol.1000271","volume":"186","author":"VS Ramgolam","year":"2011","unstructured":"Ramgolam VS, Sha Y, Marcus KL, et al. B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J Immunol. 2011;186(7):4518\u201326.","journal-title":"J Immunol"},{"issue":"6 Suppl","key":"565_CR38","first-page":"s159","volume":"22","author":"FM Hart","year":"2016","unstructured":"Hart FM, Bainbridge J. Current and emerging treatment of multiple sclerosis. Am J Manag Care. 2016;22(6 Suppl):s159\u201370.","journal-title":"Am J Manag Care"},{"key":"565_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104155","volume":"67","author":"N Sedaghat","year":"2022","unstructured":"Sedaghat N, Etemadifar M. Revisiting the antiviral theory to explain interferon-beta\u2019s effectiveness for relapsing multiple sclerosis. Mult Scler Relat Disord. 2022;67:104155.","journal-title":"Mult Scler Relat Disord"},{"key":"565_CR40","doi-asserted-by":"publisher","first-page":"1161849","DOI":"10.3389\/fimmu.2023.1161849","volume":"14","author":"G Bellucci","year":"2023","unstructured":"Bellucci G, Albanese A, Rizzi C, Rinaldi V, Salvetti M, Ristori G. The value of Interferon beta in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review. Front Immunol. 2023;14:1161849.","journal-title":"Front Immunol"},{"key":"565_CR41","doi-asserted-by":"crossref","unstructured":"PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498\u2013504.","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"565_CR42","doi-asserted-by":"crossref","unstructured":"The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology. 1999;53(4):679\u201386.","DOI":"10.1212\/WNL.53.4.679"},{"issue":"9","key":"565_CR43","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.clinthera.2007.09.025","volume":"29","author":"SR Schwid","year":"2007","unstructured":"Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29(9):2031\u201348.","journal-title":"Clin Ther"},{"issue":"10","key":"565_CR44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","volume":"7","author":"DD Mikol","year":"2008","unstructured":"Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903\u201314.","journal-title":"Lancet Neurol"},{"issue":"7","key":"565_CR45","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1177\/1352458510362442","volume":"16","author":"N De Stefano","year":"2010","unstructured":"De Stefano N, Curtin F, Stubinski B, et al. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. Mult Scler. 2010;16(7):888\u201392.","journal-title":"Mult Scler"},{"key":"565_CR46","doi-asserted-by":"crossref","unstructured":"PRISMS Study Group and the University of British Columbia MS\/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56(12):1628\u201336.","DOI":"10.1212\/WNL.56.12.1628"},{"issue":"9856","key":"565_CR47","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase\u00a03 trial. Lancet. 2012;380(9856):1819\u201328.","journal-title":"Lancet"},{"issue":"6","key":"565_CR48","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458513507821","volume":"20","author":"P Vermersch","year":"2014","unstructured":"Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase\u00a03 trial. Mult Scler. 2014;20(6):705\u201316.","journal-title":"Mult Scler"},{"issue":"1","key":"565_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","volume":"11","author":"G Comi","year":"2012","unstructured":"Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase\u00a03 randomised controlled trial. Lancet Neurol. 2012;11(1):33\u201341.","journal-title":"Lancet Neurol"},{"issue":"4","key":"565_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/jnnp-2016-314843","volume":"88","author":"G Comi","year":"2017","unstructured":"Comi G, De Stefano N, Freedman MS, et al. Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. J Neurol Neurosurg Psychiatry. 2017;88(4):285\u201394.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"565_CR51","doi-asserted-by":"crossref","unstructured":"Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56(11):1496\u2013504.","DOI":"10.1212\/WNL.56.11.1496"},{"issue":"3","key":"565_CR52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"565_CR53","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1185\/03007991003604018","volume":"26","author":"BA Cohen","year":"2010","unstructured":"Cohen BA, Rivera VM. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010;26(4):827\u201338.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"565_CR54","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P","volume":"46","author":"DK Li","year":"1999","unstructured":"Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999;46(2):197\u2013206.","journal-title":"Ann Neurol"},{"issue":"10","key":"565_CR55","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","volume":"59","author":"H Panitch","year":"2002","unstructured":"Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002;59(10):1496\u2013506.","journal-title":"Neurology"},{"issue":"6","key":"565_CR56","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00126839-200708060-00002","volume":"8","author":"A Jaber","year":"2007","unstructured":"Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, Antonelli M. The Rebif new formulation story: it\u2019s not trials and error. Drugs R D. 2007;8(6):335\u201348.","journal-title":"Drugs R D"},{"issue":"10","key":"565_CR57","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/00023210-200721100-00006","volume":"21","author":"K McKeage","year":"2007","unstructured":"McKeage K, Wagstaff AJ. Subcutaneous interferon-beta-1a: new formulation. CNS Drugs. 2007;21(10):871\u20136.","journal-title":"CNS Drugs"},{"issue":"6","key":"565_CR58","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00023210-200923060-00001","volume":"23","author":"E Portaccio","year":"2009","unstructured":"Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453\u201362.","journal-title":"CNS Drugs"},{"issue":"6","key":"565_CR59","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1212\/01.wnl.0000237994.95410.ce","volume":"67","author":"L Kappos","year":"2006","unstructured":"Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67(6):944\u201353.","journal-title":"Neurology"},{"issue":"11","key":"565_CR60","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/jnnp-2014-310024","volume":"86","author":"L Kappos","year":"2015","unstructured":"Kappos L, Kuhle J, Multanen J, et al. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry. 2015;86(11):1202\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"565_CR61","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/1756285608101379","volume":"2","author":"F Patti","year":"2009","unstructured":"Patti F, Amato MP, Bastianello S, et al. Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing-remitting multiple sclerosis: 2-year results from the COGIMUS study. Ther Adv Neurol Disord. 2009;2(2):67\u201377.","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"565_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074111","volume":"8","author":"F Patti","year":"2013","unstructured":"Patti F, Morra VB, Amato MP, et al. Subcutaneous interferon beta-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS ONE. 2013;8(8):e74111.","journal-title":"PLoS ONE"},{"issue":"1","key":"565_CR63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/1756285616671882","volume":"10","author":"Y Benesova","year":"2017","unstructured":"Benesova Y, Tvaroh A. Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon beta-1a: an observational study SKORE. Ther Adv Neurol Disord. 2017;10(1):18\u201332.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"565_CR64","first-page":"163","volume":"27","author":"F Mori","year":"2012","unstructured":"Mori F, Kusayanagi H, Buttari F, et al. Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis. Funct Neurol. 2012;27(3):163\u20138.","journal-title":"Funct Neurol"},{"issue":"2","key":"565_CR65","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"9268","key":"565_CR66","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","volume":"357","author":"G Comi","year":"2001","unstructured":"Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576\u201382.","journal-title":"Lancet"},{"issue":"6","key":"565_CR67","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/jnnp-2013-306289","volume":"85","author":"N De Stefano","year":"2014","unstructured":"De Stefano N, Comi G, Kappos L, et al. Efficacy of subcutaneous interferon beta-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2014;85(6):647\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"565_CR68","doi-asserted-by":"publisher","first-page":"101891","DOI":"10.1016\/j.msard.2019.101891","volume":"39","author":"MS Freedman","year":"2019","unstructured":"Freedman MS, Comi G, Coyle PK, et al. No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon beta-1a. Mult Scler Relat Disord. 2019;39:101891.","journal-title":"Mult Scler Relat Disord"},{"issue":"9139","key":"565_CR69","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","volume":"352","author":"L Kappos","year":"1998","unstructured":"Kappos L. Placebo-controlled multicentre randomised trial of interferon \u03b2-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139):1491\u20137.","journal-title":"Lancet"},{"issue":"10","key":"565_CR70","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","volume":"63","author":"H Panitch","year":"2004","unstructured":"Panitch H, Miller A, Paty D, Weinshenker B. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788\u201395.","journal-title":"Neurology"},{"issue":"11","key":"565_CR71","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1212\/WNL.56.11.1505","volume":"56","author":"DK Li","year":"2001","unstructured":"Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology. 2001;56(11):1505\u201313.","journal-title":"Neurology"},{"issue":"Suppl 1","key":"565_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000367614","volume":"72","author":"FD Lublin","year":"2014","unstructured":"Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72(Suppl 1):1\u20135.","journal-title":"Eur Neurol"},{"key":"565_CR73","doi-asserted-by":"publisher","first-page":"175628642110483","DOI":"10.1177\/17562864211048336","volume":"14","author":"N Frahm","year":"2021","unstructured":"Frahm N, Peters M, Batzing J, et al. Treatment patterns in pediatric patients with multiple sclerosis in Germany-a nationwide claim-based analysis. Ther Adv Neurol Disord. 2021;14:17562864211048336.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"565_CR74","doi-asserted-by":"publisher","first-page":"508","DOI":"10.5603\/PJNNS.a2020.0069","volume":"54","author":"W Brola","year":"2020","unstructured":"Brola W, Steinborn B. Pediatric multiple sclerosis - current status of epidemiology, diagnosis and treatment. Neurol Neurochir Pol. 2020;54(6):508\u201317.","journal-title":"Neurol Neurochir Pol"},{"issue":"1","key":"565_CR75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12883-018-1026-3","volume":"18","author":"R Alroughani","year":"2018","unstructured":"Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18(1):27.","journal-title":"BMC Neurol"},{"issue":"9 Suppl 2","key":"565_CR76","first-page":"S97","volume":"87","author":"A Ghezzi","year":"2016","unstructured":"Ghezzi A, Amato MP, Makhani N, Shreiner T, Gartner J, Tenembaum S. Pediatric multiple sclerosis: conventional first-line treatment and general management. Neurology. 2016;87(9 Suppl 2):S97\u2013102.","journal-title":"Neurology"},{"issue":"1","key":"565_CR77","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/1352458511430704","volume":"18","author":"T Chitnis","year":"2012","unstructured":"Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18(1):116\u201327.","journal-title":"Mult Scler"},{"issue":"11","key":"565_CR78","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","volume":"379","author":"T Chitnis","year":"2018","unstructured":"Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017\u201327.","journal-title":"N Engl J Med"},{"issue":"12","key":"565_CR79","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S1474-4422(21)00364-1","volume":"20","author":"T Chitnis","year":"2021","unstructured":"Chitnis T, Banwell B, Kappos L, et al. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase\u00a03, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(12):1001\u201311.","journal-title":"Lancet Neurol"},{"key":"565_CR80","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2018.03.007","volume":"83","author":"R Alroughani","year":"2018","unstructured":"Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S. Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS). Pediatr Neurol. 2018;83:19\u201324.","journal-title":"Pediatr Neurol"},{"key":"565_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.606418","volume":"11","author":"R Alroughani","year":"2020","unstructured":"Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M, et al. Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis. Front Neurol. 2020;11:606418.","journal-title":"Front Neurol"},{"issue":"9","key":"565_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.30439","volume":"5","author":"P Vermersch","year":"2022","unstructured":"Vermersch P, Scaramozza M, Levin S, et al. Effect of dimethyl fumarate vs interferon beta-1a in patients with pediatric-onset multiple sclerosis: The CONNECT Randomized Clinical Trial. JAMA Netw Open. 2022;5(9):e2230439.","journal-title":"JAMA Netw Open"},{"key":"565_CR83","unstructured":"Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; 2021."},{"issue":"7","key":"565_CR84","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1177\/0883073813488828","volume":"28","author":"SN Tenembaum","year":"2013","unstructured":"Tenembaum SN, Banwell B, Pohl D, et al. Subcutaneous interferon beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol. 2013;28(7):849\u201356.","journal-title":"J Child Neurol"},{"issue":"11","key":"565_CR85","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s10072-017-3091-6","volume":"38","author":"A Ghezzi","year":"2017","unstructured":"Ghezzi A, Bianchi A, Baroncini D, et al. A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-beta1a using RebiSmart-the FUTURE study. Neurol Sci. 2017;38(11):1999\u20132005.","journal-title":"Neurol Sci"},{"issue":"1","key":"565_CR86","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40263-021-00887-w","volume":"36","author":"D Jakimovski","year":"2022","unstructured":"Jakimovski D, Awan S, Eckert SP, Farooq O, Weinstock-Guttman B. Multiple sclerosis in children: differential diagnosis, prognosis, and disease-modifying treatment. CNS Drugs. 2022;36(1):45\u201359.","journal-title":"CNS Drugs"},{"key":"565_CR87","doi-asserted-by":"crossref","unstructured":"Freedman MS, Todorovi\u0107 M, Murga\u0161ov\u00e1 Z, Jack D, Korich J. Post-approval safety of subcutaneous interferon \u03b2-1a in the treatment of multiple sclerosis, with particular reference to respiratory viral infections. Consortium of Multiple Sclerosis (CMSC); National Harbor, MD, USA: DMT40; 2022.","DOI":"10.1212\/WNL.98.18_supplement.1349"},{"key":"565_CR88","first-page":"313","volume":"8","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Sperling B, Cushing K, Wenten M. Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data. Ther Clin Risk Manag. 2012;8:313\u201321.","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"565_CR89","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/jnnp-2013-307238","volume":"85","author":"E Kingwell","year":"2014","unstructured":"Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H. Assessment of cancer risk with beta-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(10):1096\u2013102.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"565_CR90","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1111\/bcp.14916","volume":"87","author":"VP Stamatellos","year":"2021","unstructured":"Stamatellos VP, Siafis S, Papazisis G. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: a disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database. Br J Clin Pharmacol. 2021;87(12):4769\u201379.","journal-title":"Br J Clin Pharmacol"},{"key":"565_CR91","unstructured":"Biogen Inc. Plegridy [package insert]. Cambridge, MA: 2014."},{"issue":"6","key":"565_CR92","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/01.wnl.0000180575.77021.c4","volume":"65","author":"R Boskovic","year":"2005","unstructured":"Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology. 2005;65(6):807\u201311.","journal-title":"Neurology"},{"issue":"11","key":"565_CR93","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40263-013-0113-7","volume":"27","author":"YD Fragoso","year":"2013","unstructured":"Fragoso YD, Adoni T, Alves-Leon SV, et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs. 2013;27(11):955\u201361.","journal-title":"CNS Drugs"},{"issue":"4","key":"565_CR94","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00415-009-5376-z","volume":"257","author":"K Hellwig","year":"2010","unstructured":"Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. 2010;257(4):580\u20133.","journal-title":"J Neurol"},{"issue":"5","key":"565_CR95","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1756285612453192","volume":"5","author":"K Hellwig","year":"2012","unstructured":"Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5(5):247\u201353.","journal-title":"Ther Adv Neurol Disord"},{"key":"565_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102694","volume":"48","author":"M Korjagina","year":"2021","unstructured":"Korjagina M, Hakkarainen KM, Burkill S, et al. Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden. Mult Scler Relat Disord. 2021;48:102694.","journal-title":"Mult Scler Relat Disord"},{"issue":"20","key":"565_CR97","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1212\/WNL.0b013e3181fd62bb","volume":"75","author":"MP Amato","year":"2010","unstructured":"Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology. 2010;75(20):1794\u2013802.","journal-title":"Neurology"},{"issue":"6","key":"565_CR98","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00415-020-09762-y","volume":"267","author":"K Hellwig","year":"2020","unstructured":"Hellwig K, Geissbuehler Y, Sabido M, et al. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. J Neurol. 2020;267(6):1715\u201323.","journal-title":"J Neurol"},{"issue":"12","key":"565_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227120","volume":"14","author":"S Burkill","year":"2019","unstructured":"Burkill S, Vattulainen P, Geissbuehler Y, et al. The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis. PLoS ONE. 2019;14(12):e0227120.","journal-title":"PLoS ONE"},{"key":"565_CR100","doi-asserted-by":"publisher","first-page":"175628642095107","DOI":"10.1177\/1756286420951072","volume":"13","author":"KM Hakkarainen","year":"2020","unstructured":"Hakkarainen KM, Juuti R, Burkill S, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord. 2020;13:1756286420951072.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"565_CR101","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/1352458509106543","volume":"15","author":"C Weber-Schoendorfer","year":"2009","unstructured":"Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. 2009;15(9):1037\u201342.","journal-title":"Mult Scler"},{"issue":"5","key":"565_CR102","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","volume":"33","author":"G Varyte","year":"2021","unstructured":"Varyte G, Arlauskiene A, Ramasauskaite D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol. 2021;33(5):378\u201383.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"4","key":"565_CR103","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11940-021-00666-4","volume":"23","author":"KM Krysko","year":"2021","unstructured":"Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of women withmultiple sclerosis planning pregnancy. Curr Treat Options Neurol. 2021;23(4):11.","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"565_CR104","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000757","volume":"7","author":"AI Ciplea","year":"2020","unstructured":"Ciplea AI, Langer-Gould A, Stahl A, et al. Safety of potential breast milk exposure to IFN-beta or glatiramer acetate: one-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e757.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"565_CR105","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/1756285608095144","volume":"1","author":"PS Sorensen","year":"2008","unstructured":"Sorensen PS. Neutralizing antibodies against interferon-beta. Ther Adv Neurol Disord. 2008;1(2):125\u201341.","journal-title":"Ther Adv Neurol Disord"},{"key":"565_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583560","volume":"11","author":"N Dunn","year":"2020","unstructured":"Dunn N, Fogdell-Hahn A, Hillert J, Spelman T. Long-term consequences of high titer neutralizing antibodies to interferon-beta in multiple sclerosis. Front Immunol. 2020;11:583560.","journal-title":"Front Immunol"},{"issue":"2","key":"565_CR107","first-page":"II15","volume":"251","author":"A Bertolotto","year":"2004","unstructured":"Bertolotto A, Deisenhammer F, Gallo P, Solberg SP. Immunogenicity of interferon beta: differences among products. J Neurol. 2004;251(2):II15\u201324.","journal-title":"J Neurol"},{"issue":"11","key":"565_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162752","volume":"11","author":"D Bachelet","year":"2016","unstructured":"Bachelet D, Hassler S, Mbogning C, et al. Occurrence of anti-drug antibodies against interferon-beta and natalizumab in multiple sclerosis: a collaborative cohort analysis. PLoS ONE. 2016;11(11):e0162752.","journal-title":"PLoS ONE"},{"issue":"5","key":"565_CR109","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/1531-8249(200011)48:5<706::AID-ANA3>3.0.CO;2-V","volume":"48","author":"C Ross","year":"2000","unstructured":"Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000;48(5):706\u201312.","journal-title":"Ann Neurol"},{"issue":"4","key":"565_CR110","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/1352458513498635","volume":"20","author":"AK Hedstrom","year":"2014","unstructured":"Hedstrom AK, Ryner M, Fink K, et al. Smoking and risk of treatment-induced neutralizing antibodies to interferon beta-1a. Mult Scler. 2014;20(4):445\u201350.","journal-title":"Mult Scler"},{"key":"565_CR111","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3389\/fimmu.2020.01527","volume":"11","author":"KE Waddington","year":"2020","unstructured":"Waddington KE, Papadaki A, Coelewij L, et al. Using serum metabolomics to predict development of anti-drug antibodies in multiple sclerosis patients treated with IFN-beta. Front Immunol. 2020;11:1527.","journal-title":"Front Immunol"},{"issue":"1","key":"565_CR112","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12916-020-01769-6","volume":"18","author":"TFM Andlauer","year":"2020","unstructured":"Andlauer TFM, Link J, Martin D, et al. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. BMC Med. 2020;18(1):298.","journal-title":"BMC Med"},{"key":"565_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103283","volume":"56","author":"MS Freedman","year":"2021","unstructured":"Freedman MS, Jack D, Murgasova Z, Todorovic M, Seitzinger A. Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis. Mult Scler Relat Disord. 2021;56:103283.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"565_CR114","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780\u20139.","journal-title":"Ann Neurol"},{"issue":"19","key":"565_CR115","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","volume":"97","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870\u201385.","journal-title":"Neurology"},{"issue":"1","key":"565_CR116","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001105","volume":"9","author":"MP Sormani","year":"2022","unstructured":"Sormani MP, Schiavetti I, Carmisciano L, et al. COVID-19 severity in multiple sclerosis: putting data into context. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1105.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"565_CR117","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00415-021-10951-6","volume":"269","author":"L Prosperini","year":"2022","unstructured":"Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies. J Neurol. 2022;269(5):2275\u201385.","journal-title":"J Neurol"},{"key":"565_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102439","volume":"45","author":"JR Ciotti","year":"2020","unstructured":"Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord. 2020;45:102439.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"565_CR119","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1212\/01.wnl.0000188901.12700.e0","volume":"65","author":"SR Schwid","year":"2005","unstructured":"Schwid SR, Decker MD, Lopez-Bresnahan M. Rebif-Influenza Vaccine Study I. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 2005;65(12):1964\u20136.","journal-title":"Neurology"},{"issue":"3","key":"565_CR120","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/ene.13537","volume":"25","author":"HK Olberg","year":"2018","unstructured":"Olberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol. 2018;25(3):527\u201334.","journal-title":"Eur J Neurol"},{"key":"565_CR121","doi-asserted-by":"crossref","unstructured":"Brill L, Rechtman A, Zveik O, et al. Effect of cladribine on COVID-19 serology responses following 2 doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. ECTRIMS; Virtual: 2021.","DOI":"10.1016\/j.msard.2021.103343"},{"key":"565_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103343","volume":"57","author":"L Brill","year":"2022","unstructured":"Brill L, Rechtman A, Zveik O, et al. Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. Mult Scler Relat Disord. 2022;57:103343.","journal-title":"Mult Scler Relat Disord"},{"key":"565_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103455","volume":"58","author":"GT Maniscalco","year":"2022","unstructured":"Maniscalco GT, Manzo V, Ferrara AL, et al. Interferon beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. Mult Scler Relat Disord. 2022;58:103455.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"565_CR124","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.1212\/WNL.0000000000013108","volume":"98","author":"C Tortorella","year":"2022","unstructured":"Tortorella C, Aiello A, Gasperini C, et al. Humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology. 2022;98(5):e541\u201354.","journal-title":"Neurology"},{"key":"565_CR125","unstructured":"National Multiple Sclerosis Society. COVID-19 vaccine guidance for people living with MS 2021 [updated September 15, 2021]. https:\/\/www.nationalmssociety.org\/coronavirus-covid-19-information\/multiple-sclerosis-and-coronavirus\/covid-19-vaccine-guidance. Accessed Oct 24, 2021."},{"key":"565_CR126","unstructured":"MS Canada. COVID-19 vaccine guidance for people living with MS 2021 [updated December 7, 2021]. https:\/\/mssociety.ca\/resources\/news\/article\/covid-19-vaccine-guidance-for-people-living-with-ms?force_lang=en_CA. Accessed Dec 7, 2021."},{"issue":"1","key":"565_CR127","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1186\/s13063-020-04812-2","volume":"21","author":"I Alavi Darazam","year":"2020","unstructured":"Alavi Darazam I, Hatami F, Rabiei MM, et al. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: a structured summary of a study protocol for a randomized controlled l trial. Trials. 2020;21(1):880.","journal-title":"Trials"},{"issue":"9","key":"565_CR128","doi-asserted-by":"publisher","first-page":"e01061-20","DOI":"10.1128\/AAC.01061-20","volume":"64","author":"E Davoudi-Monfared","year":"2020","unstructured":"Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon \u03b2-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64(9):e01061-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"565_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106688","volume":"85","author":"F Dastan","year":"2020","unstructured":"Dastan F, Nadji SA, Saffaei A, et al. Subcutaneous administration of interferon beta-1a for COVID-19: a non-controlled prospective trial. Int Immunopharmacol. 2020;85:106688.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"565_CR130","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","volume":"9","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase\u00a03 trial. Lancet Respir Med. 2021;9(12):1365\u201376.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"565_CR131","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed antiviral drugs for COVI-19 - interim WHO Solidarity Trial results. N Engl J Med. 2021;384(6):497\u2013511.","journal-title":"N Engl J Med"},{"key":"565_CR132","unstructured":"MS International Federation. Number of people newly diagnosed with MS each year 2022. https:\/\/www.atlasofms.org\/map\/united-states-of-america\/epidemiology\/number-of-people-newly-diagnosed-with-ms#about. Accessed June 10, 2022."},{"key":"565_CR133","unstructured":"MS International Federation. Atlas of MS 3rd edition 2020. https:\/\/www.msif.org\/wp-content\/uploads\/2020\/10\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf. Accessed June 10, 2022."},{"issue":"12","key":"565_CR134","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.clinthera.2014.04.002","volume":"36","author":"R Hupperts","year":"2014","unstructured":"Hupperts R, Ghazi-Visser L, Martins Silva A, et al. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Clin Ther. 2014;36(12):1946\u201357.","journal-title":"Clin Ther"},{"key":"565_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.676585","volume":"12","author":"A Allignol","year":"2021","unstructured":"Allignol A, Boutmy E, Sabido Espin M, Marhardt K, Vermersch P. Effectiveness, healthcare resource utilization and adherence to subcutaneous interferon beta-1a according to age in patients with multiple sclerosis: a cohort study using a US claims database. Front Neurol. 2021;12:676585.","journal-title":"Front Neurol"},{"issue":"1\u20132","key":"565_CR136","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000346761","volume":"70","author":"C Gobbi","year":"2013","unstructured":"Gobbi C, Zecca C, Linnebank M, et al. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies. Eur Neurol. 2013;70(1\u20132):35\u201341.","journal-title":"Eur Neurol"},{"issue":"12","key":"565_CR137","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1080\/03007995.2017.1380616","volume":"33","author":"FR Ernst","year":"2017","unstructured":"Ernst FR, Barr P, Elmor R, Wong SL. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon beta-1a or dimethyl fumarate: a real-world study. Curr Med Res Opin. 2017;33(12):2099\u2013106.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"565_CR138","first-page":"205521731881903","volume":"4","author":"JD Bowen","year":"2018","unstructured":"Bowen JD, Kozma CM, Grosso MM, Phillips AL. A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs. Mult Scler J Exp Transl Clin. 2018;4(4):2055217318819031.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"9","key":"565_CR139","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1352458514559865","volume":"21","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Jokubaitis V, Izquierdo G, et al. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(9):1159\u201371.","journal-title":"Mult Scler"},{"issue":"4","key":"565_CR140","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/ana.21757","volume":"66","author":"M Trojano","year":"2009","unstructured":"Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009;66(4):513\u201320.","journal-title":"Ann Neurol"},{"issue":"8","key":"565_CR141","first-page":"650","volume":"21","author":"MY Smith","year":"2015","unstructured":"Smith MY, Sabido-Espin M, Trochanov A, et al. Postmarketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: a retrospective administrative claims analysis. J Manag Care Spec Pharm. 2015;21(8):650\u201360.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"565_CR142","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1517\/17425247.2015.1057567","volume":"12","author":"A Bayas","year":"2015","unstructured":"Bayas A, Ouallet JC, Kallmann B, et al. Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart\u00ae in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015;12(8):1239\u201350.","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"565_CR143","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1191\/1352458505ms1197oa","volume":"11","author":"D Mikol","year":"2005","unstructured":"Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J, Rebiject Study Group. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11(5):585\u201391.","journal-title":"Mult Scler"},{"issue":"1","key":"565_CR144","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7224\/1537-2073-14.1.46","volume":"14","author":"TM Stewart","year":"2012","unstructured":"Stewart TM, Tran ZV. Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions. Int J MS Care. 2012;14(1):46\u201353.","journal-title":"Int J MS Care"},{"issue":"1","key":"565_CR145","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13104-016-1948-z","volume":"9","author":"VA Devonshire","year":"2016","unstructured":"Devonshire VA, Feinstein A, Moriarty P. Adherence to interferon beta-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Res Notes. 2016;9(1):148.","journal-title":"BMC Res Notes"},{"issue":"6","key":"565_CR146","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/1756285614549554","volume":"7","author":"MS Freedman","year":"2014","unstructured":"Freedman MS. Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. Ther Adv Neurol Disord. 2014;7(6):279\u201388.","journal-title":"Ther Adv Neurol Disord"},{"issue":"23","key":"565_CR147","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1212\/WNL.0b013e318258f7d4","volume":"78","author":"MS Freedman","year":"2012","unstructured":"Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology. 2012;78(23):1877\u201385.","journal-title":"Neurology"},{"issue":"5","key":"565_CR148","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000477","volume":"5","author":"X Montalban","year":"2018","unstructured":"Montalban X, Leist TP, Cohen BA, et al. Cladribine tablets added to IFN-beta in active relapsing MS: the ONWARD study. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e477.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"565_CR149","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fimmu.2013.00281","volume":"4","author":"AT Reder","year":"2013","unstructured":"Reder AT, Feng X. Aberrant type\u00a0I interferon regulation in autoimmunity: opposite directions in MS and SLE, shaped by evolution and body ecology. Front Immunol. 2013;4:281.","journal-title":"Front Immunol"},{"issue":"20","key":"565_CR150","doi-asserted-by":"publisher","first-page":"e1906","DOI":"10.1212\/WNL.0000000000008445","volume":"93","author":"R Hupperts","year":"2019","unstructured":"Hupperts R, Smolders J, Vieth R, et al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a. Neurology. 2019;93(20):e1906\u201316.","journal-title":"Neurology"},{"issue":"1\u20132","key":"565_CR151","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jns.2011.04.013","volume":"311","author":"J Smolders","year":"2011","unstructured":"Smolders J, Hupperts R, Barkhof F, et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci. 2011;311(1\u20132):44\u20139.","journal-title":"J Neurol Sci"},{"issue":"6","key":"565_CR152","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000622","volume":"6","author":"X Feng","year":"2019","unstructured":"Feng X, Wang Z, Howlett-Prieto Q, Einhorn N, Causevic S, Reder AT. Vitamin D enhances responses to interferon-beta in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e622.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"565_CR153","volume":"2012","author":"J Aivo","year":"2012","unstructured":"Aivo J, Lindsrom BM, Soilu-Hanninen M. A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Mult Scler Int. 2012;2012: 802796.","journal-title":"Mult Scler Int"},{"issue":"5","key":"565_CR154","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/jnnp-2011-301876","volume":"83","author":"M Soilu-Hanninen","year":"2012","unstructured":"Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(5):565\u201371.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"565_CR155","first-page":"16","volume":"13","author":"K Ghasami","year":"2016","unstructured":"Ghasami K, Faraji F, Fazeli M, Ghazavi A, Mosayebi G. Interferon beta-1a and atorvastatin in the treatment of multiple sclerosis. Iran J Immunol. 2016;13(1):16\u201326.","journal-title":"Iran J Immunol"},{"issue":"4","key":"565_CR156","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/1352458509358909","volume":"16","author":"R Lanzillo","year":"2010","unstructured":"Lanzillo R, Orefice G, Quarantelli M, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010;16(4):450\u20134.","journal-title":"Mult Scler"},{"issue":"22","key":"565_CR157","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1212\/01.wnl.0000349667.27301.c8","volume":"72","author":"S Markovic-Plese","year":"2009","unstructured":"Markovic-Plese S, Jewells V, Speer D. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2009;72(22):1965 (author reply-6).","journal-title":"Neurology"},{"issue":"17","key":"565_CR158","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.2146\/ajhp110675","volume":"69","author":"S Bhardwaj","year":"2012","unstructured":"Bhardwaj S, Coleman CI, Sobieraj DM. Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis. Am J Health Syst Pharm. 2012;69(17):1494\u20139.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"565_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086663","volume":"9","author":"CP Kamm","year":"2014","unstructured":"Kamm CP, El-Koussy M, Humpert S, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. PLoS ONE. 2014;9(1):e86663.","journal-title":"PLoS ONE"},{"key":"565_CR160","first-page":"6198530","volume":"2017","author":"PK Coyle","year":"2017","unstructured":"Coyle PK. Pharmacogenetic biomarkers to predict treatment response in multiple sclerosis: current and future perspectives. Mult Scler Int. 2017;2017:6198530.","journal-title":"Mult Scler Int"},{"key":"565_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577715","volume":"360","author":"MS Freedman","year":"2021","unstructured":"Freedman MS, Wojcik J, Holmberg KH, et al. Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION. J Neuroimmunol. 2021;360:577715.","journal-title":"J Neuroimmunol"},{"key":"565_CR162","unstructured":"Dicillo EB, Kountikov E, Zhu M, et al. Genome-wide mapping of patient autoantibody targets to understand and predict multiple sclerosis pathogenesis and patient responses to interferon beta-1a therapy. 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); Switzerland: 2021."},{"issue":"3","key":"565_CR163","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12035-013-8463-1","volume":"48","author":"M Hecker","year":"2013","unstructured":"Hecker M, Hartmann C, Kandulski O, et al. Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients\u2019 individual gene expression in peripheral blood. Mol Neurobiol. 2013;48(3):737\u201356.","journal-title":"Mol Neurobiol"},{"issue":"8","key":"565_CR164","doi-asserted-by":"publisher","first-page":"16087","DOI":"10.3390\/ijms140816087","volume":"14","author":"M Hecker","year":"2013","unstructured":"Hecker M, Thamilarasan M, Koczan D, et al. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Mol Sci. 2013;14(8):16087\u2013110.","journal-title":"Int J Mol Sci"},{"key":"565_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2020.108322","volume":"785","author":"L Martinez-Aguilar","year":"2020","unstructured":"Martinez-Aguilar L, Perez-Ramirez C, Maldonado-Montoro MDM, et al. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta. Mutat Res Rev Mutat Res. 2020;785:108322.","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"2","key":"565_CR166","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41397-019-0114-0","volume":"20","author":"SA Ayatollahi","year":"2020","unstructured":"Ayatollahi SA, Ghafouri-Fard S, Taheri M, Noroozi R. The efficacy of interferon-beta therapy in multiple sclerosis patients: investigation of the RORA gene as a predictive biomarker. Pharmacogenomics J. 2020;20(2):271\u20136.","journal-title":"Pharmacogenomics J"},{"key":"565_CR167","doi-asserted-by":"crossref","unstructured":"Kuhle J, Leppert D, Comi G, et al. Baseline serum neurofilament light chain levels predict conversion to McDonald 2005 multiple sclerosis (MS) within 2 years of a first clinical demyelinating event in patients with MS. AAN 2021 Virtual Congress; April 17\u201322, 2021. Program number P15.001","DOI":"10.1212\/WNL.96.15_supplement.1908"},{"key":"565_CR168","doi-asserted-by":"crossref","unstructured":"Kuhle J, Leppert D, Comi G, et al. Investigating the correlation between serum neurofilament light chain (sNfL) concentration and magnetic resonance imaging (MRI)-outcomes in patients with a first clinical demyelinating Event in the REFLEX Trial. AAN 2021 Virtual Congress; April 17\u201322, 2021. Program number P15.005","DOI":"10.1212\/WNL.96.15_supplement.1116"},{"key":"565_CR169","unstructured":"Coray M, Seitzinger A, Roy S, et al. Exploratory analysis of serum GDF-15 levels in patients receiving subcutaneous interferon \u03b2-1a in the REFLEX Trial. ECTRIMS 2021 Virtual Congress October 13\u201315, 2021. P674."},{"key":"565_CR170","doi-asserted-by":"publisher","first-page":"175628642097522","DOI":"10.1177\/1756286420975223","volume":"13","author":"T Berger","year":"2020","unstructured":"Berger T, Adamczyk-Sowa M, Csepany T, et al. Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. Ther Adv Neurol Disord. 2020;13:1756286420975223.","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00565-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00565-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00565-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T11:25:09Z","timestamp":1710847509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00565-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":170,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00565-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark S. Freedman has received honoraria or consultation fees from Actelion (Janssen\/J&J), Alexion\/Astra Zeneca, Biogen, Celgene (BMS), Find Therapeutics, Hoffmann La Roche, Horizon Therapeutics, Merck and Co, Novartis, Sandoz, Sanofi-Genzyme, and Teva Canada Innovation; has received research support unrelated to this study from Sanofi-Genzyme Canada, Hoffman-La Roche, and Merck Healthcare KGaA, Darmstadt, Germany; was a member of a company advisory board, board of directors, or other similar group for Actelion (Janssen\/J&J), Alexion\/Astra Zeneca, Atara Biotherapeutics, Bayer Healthcare, Biogen Idec, Celgene (BMS), Horizon Therapeutics, Hoffman La-Roche, Merck Healthcare KGaA, Darmstadt, Germany, Novartis, Sanofi-Genzyme, and Teva Canada Innovation; and has been a participant in a company sponsored speaker\u2019s bureau for Sanofi-Genzyme and Merck Healthcare KGaA, Darmstadt, Germany). Patricia K. Coyle declares receiving consulting & nonbranded speaker fees from Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Horizon Therapeutics, Janssen, Mylan, Novartis, Sanofi Genzyme, TG Therapeutics, and Viela Bio; and research support from Actelion, Alkermes, Celgene, CorEvitas LLC, Genentech\/Roche, MedDay, NINDS, Novartis, and Sanofi Genzyme. Kerstin Hellwig has received consulting fees, fees for non-CME services, and speaker\u2019s bureau from Bayer, Biogen, Merck and Co, Novartis, Roche, Sanofi, and Teva. Barry Singer has received research support from AbbVie, Biogen, Greenwich Biosciences, Novartis, and Sanofi Genzyme; and consulting and\/or speaking fees from AbbVie, Alexion, Biogen, Bristol Myers Squibb, Cigna, Merck Healthcare KGaA, Darmstadt, Germany, Janssen, Genentech, Greenwich Biosciences, Horizon, Novartis, Octave Bioscience, Roche, Sanofi Genzyme, and TG Therapeutics. Daniel Wynn \u2013 employer has received research funding, speaker fees, or served as expert witness for AbbVie, Adamas, Allergan, ANI Pharma, Avanir, Banner Life, Biogen, Bristol Myers Squibb, Chugai, Eli Lilly, Merck Healthcare KGaA, Darmstadt, Germany, Genentech, GW Therapeutics, Immunic, InnoCare, Janssen, Jazz Pharmaceuticals, Mallinckrodt, MAPI Therapeutics, Mylan, National MS Society, Novartis, SanBio, Sanofi Genzyme, UCB Biopharma, Viela Bio, Teva Pharmaceuticals, and TG Therapeutics. Bianca Weinstock-Guttman has participated in speaker\u2019s bureaus and\/or served as a consultant for Bayer, Biogen, Celgene\/Bristol Meyers Squibb, Merck Healthcare KGaA, Genentech, Janssen and Horizon, Novartis, and Sanofi Genzyme; has received grant\/research support from the agencies listed in the previous sentence; and serves in the editorial board for BMJ Neurology, Children, CNS Drugs, Frontiers Epidemiology, and MS International. Silva Markovic-Plese has received grant research support from Bristol Myers Squibb and honoraria from Genentech and Janssen Pharmaceuticals for participation in editorial boards. Andrew Galazka has received consulting fees from the healthcare business of Merck Healthcare KGaA, Darmstadt, Germany. Fernando Dangond was formerly an employee of EMD Serono Research & Development Institute,\u00a0Inc.,\u00a0Billerica, MA, USA,\u00a0an affiliate\u00a0of Merck KGaA, and is currently an employee of Bristol Myers Squibb. Julie Korich is an employee of EMD Serono Inc., Rockland, MA, USA, an affiliate of Merck KGaA. Anthony T. Reder has received consulting fees from Acorda, Bayer, Biogen, BMS, Merck Healthcare KGaA, Genentech, Genzyme, Novartis, Pfizer, Mallinckrodt (formerly Questcor), Sanofi, and Teva Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}